08:51 AM EDT, 06/17/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that it had submitted a Biologics License Application to the US Food and Drug Administration for subcutaneous amivantamab for certain patients with non-small cell lung cancer.

The company said the application is based on a late-stage study that showed that the subcutaneous form was as effective as intravenous administration, with shorter administration time, fewer infusion-related reactions, and improved survival outcomes.

Price: 145.84, Change: +0.30, Percent Change: +0.21